SE464135B - Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov - Google Patents

Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov

Info

Publication number: SE464135B
Authority: SE; Sweden
Prior art keywords: protein; thrombin; coagulation; plasma; fixa
Prior art date: 1989-07-14

Application number

SE8902532A

Other languages

English (en)

Swedish (sv)

Other versions

SE8902532D0 (sv

SE8902532L (sv

Inventor

S Rosen

Original Assignee

Kabivitrum Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-14

Filing date

1989-07-14

Publication date

1991-03-11

1989-07-14 Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab

1989-07-14 Priority to SE8902532A priority Critical patent/SE464135B/sv

1989-07-14 Publication of SE8902532D0 publication Critical patent/SE8902532D0/xx

1990-07-04 Priority to DE69022425T priority patent/DE69022425T2/de

1990-07-04 Priority to AU60533/90A priority patent/AU6053390A/en

1990-07-04 Priority to JP2510438A priority patent/JP2892828B2/ja

1990-07-04 Priority to IE243190A priority patent/IE902431A1/en

1990-07-04 Priority to EP90910954A priority patent/EP0486515B1/de

1990-07-04 Priority to PCT/SE1990/000478 priority patent/WO1991001382A1/en

1990-07-04 Priority to ES90910954T priority patent/ES2079481T3/es

1990-07-04 Priority to AT90910954T priority patent/ATE127853T1/de

1990-07-04 Priority to CA002063564A priority patent/CA2063564A1/en

1990-07-04 Priority to US07/793,342 priority patent/US5439802A/en

1990-07-04 Priority to DK90910954.8T priority patent/DK0486515T3/da

1991-01-15 Publication of SE8902532L publication Critical patent/SE8902532L/

1991-03-11 Publication of SE464135B publication Critical patent/SE464135B/sv

1992-01-09 Priority to NO920125A priority patent/NO920125D0/no

Links

238000000034 method Methods 0.000 title claims description 76
108090000623 proteins and genes Proteins 0.000 title claims description 19
102000004169 proteins and genes Human genes 0.000 title claims description 19
230000005714 functional activity Effects 0.000 title claims description 12
229940096437 Protein S Drugs 0.000 claims abstract description 84
102000029301 Protein S Human genes 0.000 claims abstract description 83
108010066124 Protein S Proteins 0.000 claims abstract description 83
229960004072 thrombin Drugs 0.000 claims abstract description 54
108090000190 Thrombin Proteins 0.000 claims abstract description 53
101800004937 Protein C Proteins 0.000 claims abstract description 46
102000017975 Protein C Human genes 0.000 claims abstract description 46
229960000856 protein c Drugs 0.000 claims abstract description 46
101800001700 Saposin-D Proteins 0.000 claims abstract description 45
230000015572 biosynthetic process Effects 0.000 claims abstract description 19
230000015271 coagulation Effects 0.000 claims description 34
238000005345 coagulation Methods 0.000 claims description 34
239000000758 substrate Substances 0.000 claims description 28
230000008569 process Effects 0.000 claims description 20
241000283690 Bos taurus Species 0.000 claims description 19
150000003904 phospholipids Chemical class 0.000 claims description 17
102100026735 Coagulation factor VIII Human genes 0.000 claims description 16
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 16
108090000790 Enzymes Proteins 0.000 claims description 14
102000004190 Enzymes Human genes 0.000 claims description 14
229940088598 enzyme Drugs 0.000 claims description 14
108010094028 Prothrombin Proteins 0.000 claims description 10
102100027378 Prothrombin Human genes 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
229940039716 prothrombin Drugs 0.000 claims description 9
238000003776 cleavage reaction Methods 0.000 claims description 8
230000007017 scission Effects 0.000 claims description 8
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 7
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 7
239000003114 blood coagulation factor Substances 0.000 claims description 7
239000003153 chemical reaction reagent Substances 0.000 claims description 7
230000002596 correlated effect Effects 0.000 claims description 5
101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 claims description 3
102000052932 human PROS1 Human genes 0.000 claims description 3
229940099815 human protein s Drugs 0.000 claims description 3
238000005375 photometry Methods 0.000 claims description 2
238000011533 pre-incubation Methods 0.000 claims 1
238000010188 recombinant method Methods 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 21
210000002381 plasma Anatomy 0.000 description 54
230000004913 activation Effects 0.000 description 16
239000007983 Tris buffer Substances 0.000 description 10
238000011534 incubation Methods 0.000 description 10
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
208000007536 Thrombosis Diseases 0.000 description 9
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 8
108010073385 Fibrin Proteins 0.000 description 7
206010051292 Protein S Deficiency Diseases 0.000 description 7
230000009471 action Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
102000009123 Fibrin Human genes 0.000 description 6
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 6
239000012190 activator Substances 0.000 description 6
229950003499 fibrin Drugs 0.000 description 6
102000055691 human APC Human genes 0.000 description 6
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
102100026966 Thrombomodulin Human genes 0.000 description 5
108010079274 Thrombomodulin Proteins 0.000 description 5
239000001110 calcium chloride Substances 0.000 description 5
235000011148 calcium chloride Nutrition 0.000 description 5
229910001628 calcium chloride Inorganic materials 0.000 description 5
108010000020 Platelet Factor 3 Proteins 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000035602 clotting Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 3
ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 3
229920002079 Ellagic acid Polymers 0.000 description 3
201000005660 Protein C Deficiency Diseases 0.000 description 3
108010000499 Thromboplastin Proteins 0.000 description 3
102000002262 Thromboplastin Human genes 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000011575 calcium Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
229960002852 ellagic acid Drugs 0.000 description 3
235000004132 ellagic acid Nutrition 0.000 description 3
230000006870 function Effects 0.000 description 3
208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 3
238000010915 one-step procedure Methods 0.000 description 3
239000003998 snake venom Substances 0.000 description 3
YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
239000005995 Aluminium silicate Substances 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010051508 Preconativ Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
235000012211 aluminium silicate Nutrition 0.000 description 2
230000002429 anti-coagulating effect Effects 0.000 description 2
230000010100 anticoagulation Effects 0.000 description 2
239000004019 antithrombin Substances 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229940012957 plasmin Drugs 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
FNQLUUASYSCLNV-AWEZNQCLSA-N (2s)-2-(cyclohexylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical group C([C@@H](C(=O)O)NC1CCCCC1)C1=CC=C(O)C=C1 FNQLUUASYSCLNV-AWEZNQCLSA-N 0.000 description 1
BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical compound O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 description 1
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
GONFBOIJNUKKST-UHFFFAOYSA-N 5-ethylsulfanyl-2h-tetrazole Chemical compound CCSC=1N=NNN=1 GONFBOIJNUKKST-UHFFFAOYSA-N 0.000 description 1
241000271045 Agkistrodon contortrix contortrix Species 0.000 description 1
201000005657 Antithrombin III deficiency Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
101100129922 Caenorhabditis elegans pig-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
101100520057 Drosophila melanogaster Pig1 gene Proteins 0.000 description 1
206010014522 Embolism venous Diseases 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
108010054964 H-hexahydrotyrosyl-alanyl-arginine-4-nitroanilide Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
108010039286 S 2238 Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
208000014763 coagulation protein disease Diseases 0.000 description 1
230000004154 complement system Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940070376 protein Drugs 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
108010026668 snake venom protein C activator Proteins 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000012085 test solution Substances 0.000 description 1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
208000004043 venous thromboembolism Diseases 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2337/00—N-linked chromogens for determinations of peptidases and proteinases
- C12Q2337/10—Anilides
- C12Q2337/12—Para-Nitroanilides p-NA
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/4609—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates from reptiles
- G01N2333/4613—Snake venom
- G01N2333/462—Snake venom from Agkistrodon sp., e.g. acutase, ACTE
- G01N2333/4626—Snake venom from Agkistrodon sp., e.g. acutase, ACTE from Agkistrodon contortrix contortrix (copperhead snake); Protac (R)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/9645—Factor IX (3.4.21.22)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96461—Protein C (3.4.21.69)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Hematology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

SE8902532A 1989-07-14 1989-07-14 Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov SE464135B (sv)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
SE8902532A SE464135B (sv)	1989-07-14	1989-07-14	Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
DK90910954.8T DK0486515T3 (da)	1989-07-14	1990-07-04	Fremgangsmåde til bestemmelse af den funktionelle aktivitet af frit protein S eller protein C i en plasmaprøve
PCT/SE1990/000478 WO1991001382A1 (en)	1989-07-14	1990-07-04	A method for determining the functional activity of free protein s or protein c in a plasma sample
AT90910954T ATE127853T1 (de)	1989-07-14	1990-07-04	Verfahren zur bestimmung der funktionellen wirkung von freiem protein s oder protein c in einer plasmaprobe.
JP2510438A JP2892828B2 (ja)	1989-07-14	1990-07-04	血漿プロテインの検定方法
IE243190A IE902431A1 (en)	1989-07-14	1990-07-04	Assaying of plasma proteins
EP90910954A EP0486515B1 (de)	1989-07-14	1990-07-04	Verfahren zur Bestimmung der funktionellen Wirkung von freiem Protein S oder Protein C in einer Plasmaprobe
DE69022425T DE69022425T2 (de)	1989-07-14	1990-07-04	Verfahren zur Bestimmung der funktionellen Wirkung von freiem Protein S oder Protein C in einer Plasmaprobe.
ES90910954T ES2079481T3 (es)	1989-07-14	1990-07-04	Un procedimiento para la determinacion de la actividad funcional de la proteina s o de la proteina c libre en una muestra de plasma.
AU60533/90A AU6053390A (en)	1989-07-14	1990-07-04	A method for determining the functional activity of free protein s or protein c in a plasma sample
CA002063564A CA2063564A1 (en)	1989-07-14	1990-07-04	Method for determining the functional activity of free protein s or protein c in a plasma sample
US07/793,342 US5439802A (en)	1989-07-14	1990-07-04	Method for determining the functional activity of free protein S or protein C in a plasma sample
NO920125A NO920125D0 (no)	1989-07-14	1992-01-09	Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fri protein s eller protein c i en plasma-proeve

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8902532A SE464135B (sv)	1989-07-14	1989-07-14	Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov

Publications (3)

Publication Number	Publication Date
SE8902532D0 SE8902532D0 (sv)	1989-07-14
SE8902532L SE8902532L (sv)	1991-01-15
SE464135B true SE464135B (sv)	1991-03-11

Family

ID=20376547

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8902532A SE464135B (sv)	1989-07-14	1989-07-14	Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov

Country Status (13)

Country	Link
US (1)	US5439802A (de)
EP (1)	EP0486515B1 (de)
JP (1)	JP2892828B2 (de)
AT (1)	ATE127853T1 (de)
AU (1)	AU6053390A (de)
CA (1)	CA2063564A1 (de)
DE (1)	DE69022425T2 (de)
DK (1)	DK0486515T3 (de)
ES (1)	ES2079481T3 (de)
IE (1)	IE902431A1 (de)
NO (1)	NO920125D0 (de)
SE (1)	SE464135B (de)
WO (1)	WO1991001382A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993010261A1 (en) *	1991-11-13	1993-05-27	Dahlbaeck Bjoern	Method for the diagnosis of blood coagulation disorders
US5443960A (en) *	1991-11-13	1995-08-22	Dahlbaeck; Bjoern	Method for the diagnosis of blood coagulation disorders
WO1996014581A1 (en) *	1994-11-08	1996-05-17	Global Hemostasis Institute Mgr Ab	Method, reagent and kit for analysis of haemostatic activity
WO1998044000A1 (en) *	1997-04-03	1998-10-08	T.A.C. Thrombosis And Coagulation Aktiebolag	Recombinant protein c and protein s variants

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4006634A1 (de) *	1990-03-03	1991-09-05	Behringwerke Ag	Funktioneller test zur bestimmung der protein s-aktivitaet
ES2115679T3 (es) *	1991-10-04	1998-07-01	Dade Behring Inc	Preparacion de reactivos de tiempo de protrombina a partir de factor de tejido humano recombinante y de fosfolipidos sinteticos y naturales purificados.
AU2870992A (en) *	1991-10-04	1993-05-03	Board Of Regents Of The University Of Nebraska, The	A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) *	1991-10-04	1998-02-10	Matschiner; John T.	Thrombomodulin-based coagulometric assay of the protein C system
US5308756A (en) *	1991-11-20	1994-05-03	Baxter Diagnostics Inc.	Protein S chromogenic assay
DE4229933A1 (de) *	1992-09-08	1994-03-10	Max Planck Gesellschaft	Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
WO1994017415A1 (en)	1993-01-29	1994-08-04	Dahlbaeck Bjoern	Novel anticoagulant cofactor activity
DE59410041D1 (de) *	1993-12-03	2002-03-21	Baxter Ag	Test zur Bestimmung der Empfindlichkeit gegenüber aktiviertem Protein C
AUPM731394A0 (en) *	1994-08-05	1994-09-01	Life Therapeutics Limited	Improved activated protein c resistance test
DE4427785A1 (de) *	1994-08-08	1996-02-15	Behringwerke Ag	Verfahren zum Nachweis von Störungen des Protein C/Protein S-Systems
US5780255A (en) *	1995-06-09	1998-07-14	Instrumentation Laboratory, S.P.A.	Protein C pathway screening test
US5766869A (en) *	1995-11-30	1998-06-16	Ahs Hospital Corp.	Factor V ratio blood test for susceptibility to thromboembolism
US6379975B1 (en)	1996-11-27	2002-04-30	T.A.C. Thrombosis And Coagulation Aktiebolag	Methods and reagents for determining protein S
AUPP159698A0 (en)	1998-02-02	1998-02-26	Life Therapeutics Limited	Improved blood coagulation test
DE69801210T2 (de)	1998-03-19	2002-05-02	Instrumentation Laboratory S.P.A., Mailand/Milano	Verbesserte in vitro Verfahren, Testkits und Reagenzien zum Screening von Blutgerinnungsfehlern
US6855509B2 (en) *	2000-12-19	2005-02-15	Instrumentation Laboratory Company	Protein S functional assay and kit therefor
RU2270020C2 (ru) *	2004-04-20	2006-02-20	Государственное учреждение Кировский научно-исследовательский институт гематологии и переливания крови (ГУ Книги ПК)	Способ получения контрольной плазмы с нормальным уровнем протромбинового комплекса
JP5839256B2 (ja)	2011-03-14	2016-01-06	学校法人九州文化学園	総プロテインｓ異常症の検出方法において用いる試薬
CN106153612A (zh) *	2015-12-04	2016-11-23	上海贞元诊断用品科技有限公司	抗凝血酶活性检测试剂及其制备方法和应用
CN120761656A (zh) *	2025-09-03	2025-10-10	湖南赛新生物科技有限公司	一种高稳定性蛋白s活性测定试剂盒及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4657894A (en) *	1983-03-31	1987-04-14	Scripps Clinic & Research Foundation	New factor VIII coagulant polypeptides
DE3516579A1 (de) *	1984-11-19	1986-05-22	Boehringer Mannheim Gmbh, 6800 Mannheim	Gerinnungstest auf teststreifen
US4775624A (en) *	1985-02-08	1988-10-04	Eli Lilly And Company	Vectors and compounds for expression of human protein C
DE3607559A1 (de) *	1986-03-07	1987-09-10	Boehringer Mannheim Gmbh	Verfahren zur photometrischen bestimmung der protein c- und/oder protein s-aktivitaet
US4908314A (en) *	1987-07-02	1990-03-13	American National Red Cross	Protein C activator
DE3724443A1 (de) *	1987-07-23	1989-02-02	Max Planck Gesellschaft	Funktioneller test zur bestimmung der protein s-aktivitaet
JP2739050B2 (ja) *	1988-01-28	1998-04-08	ヘキスト薬品工業株式会社	抗血液凝固剤
US5051357A (en) *	1989-07-14	1991-09-24	Board Of Trustees Operating Michigan State University	Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor

1989
- 1989-07-14 SE SE8902532A patent/SE464135B/sv not_active IP Right Cessation
1990
- 1990-07-04 AU AU60533/90A patent/AU6053390A/en not_active Abandoned
- 1990-07-04 WO PCT/SE1990/000478 patent/WO1991001382A1/en not_active Ceased
- 1990-07-04 CA CA002063564A patent/CA2063564A1/en not_active Abandoned
- 1990-07-04 ES ES90910954T patent/ES2079481T3/es not_active Expired - Lifetime
- 1990-07-04 JP JP2510438A patent/JP2892828B2/ja not_active Expired - Fee Related
- 1990-07-04 IE IE243190A patent/IE902431A1/en unknown
- 1990-07-04 EP EP90910954A patent/EP0486515B1/de not_active Expired - Lifetime
- 1990-07-04 AT AT90910954T patent/ATE127853T1/de not_active IP Right Cessation
- 1990-07-04 DK DK90910954.8T patent/DK0486515T3/da active
- 1990-07-04 DE DE69022425T patent/DE69022425T2/de not_active Expired - Fee Related
- 1990-07-04 US US07/793,342 patent/US5439802A/en not_active Expired - Fee Related
1992
- 1992-01-09 NO NO920125A patent/NO920125D0/no unknown

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993010261A1 (en) *	1991-11-13	1993-05-27	Dahlbaeck Bjoern	Method for the diagnosis of blood coagulation disorders
US5443960A (en) *	1991-11-13	1995-08-22	Dahlbaeck; Bjoern	Method for the diagnosis of blood coagulation disorders
WO1996014581A1 (en) *	1994-11-08	1996-05-17	Global Hemostasis Institute Mgr Ab	Method, reagent and kit for analysis of haemostatic activity
US6156530A (en) *	1994-11-08	2000-12-05	Global Hemostasis Institute Mgr Ab	Method for analysis of haemostatic activity
WO1998044000A1 (en) *	1997-04-03	1998-10-08	T.A.C. Thrombosis And Coagulation Aktiebolag	Recombinant protein c and protein s variants

Also Published As

Publication number	Publication date
EP0486515A1 (de)	1992-05-27
DE69022425D1 (de)	1995-10-19
JP2892828B2 (ja)	1999-05-17
EP0486515B1 (de)	1995-09-13
DE69022425T2 (de)	1996-05-02
IE902431A1 (en)	1991-06-19
WO1991001382A1 (en)	1991-02-07
SE8902532D0 (sv)	1989-07-14
AU6053390A (en)	1991-02-22
SE8902532L (sv)	1991-01-15
ES2079481T3 (es)	1996-01-16
US5439802A (en)	1995-08-08
JPH04506603A (ja)	1992-11-19
NO920125L (no)	1992-01-09
ATE127853T1 (de)	1995-09-15
DK0486515T3 (da)	1996-01-29
NO920125D0 (no)	1992-01-09
CA2063564A1 (en)	1991-01-15

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8902532-4

Effective date: 19930204

Format of ref document f/p: F

Publication	Publication Date	Title
SE464135B (sv)	1991-03-11	Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
Martinoli et al.	1986	Fast functional protein C assay using protac® a novel protein C activator
Conard et al.	1983	Molar antithrombin concentration in normal human plasma
US6911334B2 (en)	2005-06-28	Protease for activating clotting factor VII
JP2562000B2 (ja)	1996-12-11	血液凝固疾患の診断方法
DK171086B1 (da)	1996-05-28	Fremgangsmåde til fotometrisk bestemmelse af protein C- og/eller protein S-aktivitet
US20030199014A1 (en)	2003-10-23	In vitro methods for screening for blood coagulation disorders using metal ions
US6090570A (en)	2000-07-18	Method for specifically detecting a coagulation factor V which has an increased stability toward activated protein C in the activated state
US5726028A (en)	1998-03-10	Method for detecting disturbances of the protein c/protein s system
Gempeler-Messina et al.	2002	Protein C activators from snake venoms and their diagnostic use
CA2154080C (en)	2006-03-21	Novel anticoagulant cofactor activity
Michiels et al.	1998	Laboratory diagnosis of hereditary thrombophilia
JPH11507542A (ja)	1999-07-06	プロトロンビン誘導体
US20090221012A1 (en)	2009-09-03	Method for Detecting Procoagulant Phospholipid
Marsh	1998	Use of snake venom fractions in the coagulation laboratory
AU729843B2 (en)	2001-02-08	Method for the functional detection of disorders in the protein C system
Sala et al.	1987	Dysfunctional activated protein C (PC Cadiz) in a patient with thrombotic disease
Mannhalter	1987	Biochemical and functional properties of factor XI and prekallikrein
Triplett et al.	1981	New methods in coagulation
Thiel et al.	1986	A simplified functional assay for protein C in plasma samples
Esmon	1984	The role of protein C and thrombomodulin in the regulation of blood coagulation
Maurissen	2009	Characterization of anticoagulant functions of protein S
Hirbawi	2009	Cofactor Control of a Vital Enzymatic Reaction: The Effect of Factor Va on Thrombin Formation During Blood Coagulation
Griffin	1989	Deficiencies of Protein C and Protein S and Thromoembolic Disease